$PVCT, Last Price 0.0165 Provectus News Pr
Post# of 103076
Posted On: 11/30/2016 4:51:13 PM
$PVCT, Last Price 0.0165
Provectus News
Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency
Company Expects to Submit a Plan to Regain Compliance
Wednesday November 30, 2016
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company" , today announced receipt of notification (the "Deficiency Letter" from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.
Specifically, the Deficiency Letter indicated that the Company is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide (requiring stockholders' equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years). As of September 30, 2016, the Company had stockholders' equity of approximately $5.3 million. The Company is required to submit a plan to the NYSE MKT by December 23, 2016 advising of actions it has taken or will take to regain compliance with the continued listing standards by May 23, 2018. The Company's management is exploring its options moving forward. Currently, the Company intends to submit a plan by the December 23, 2016 deadline. If the Company does not submit a plan or if the plan is not accepted, NYSE Regulation will take action to cite the Company's noncompliance with Section 1003(a)(iii) of the NYSE MKT Company Guide as an additional basis for delisting, in addition to the "abnormally low" trading price of the shares of the Company's common stock, which was the basis for NYSE MKT's determination on October 13, 2016 to immediately suspend trading of the Company's common stock and class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (the "Listed Warrants" and commence delisting procedures, which determination the Company is currently appealing. If the plan is accepted, the Company will be subject to periodic reviews and continued compliance with the plan. If the Company is not in compliance with the continued listing standards as of May 23, 2018, or does not make progress consistent with the plan, NYSE MKT will initiate delisting proceedings.
The Company's common stock and Listed Warrants currently trade on the OTCQB under the symbols "PVCT" and "PVCTWS," respectively, and the Company expects that these securities will continue to trade on the OTCQB while it attempts to regain compliance with the NYSE MKT listing standards noted above. The NYSE MKT notification does not affect the Company's business operations or its SEC reporting requirements.
The complete press release is available at http://www.provectusbio.com/news/press-releas...20161130-1 on the Provectus website.
Read More: http://investorshangout.com/post/view?id=4197...z4RX09DT00
Provectus News
Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency
Company Expects to Submit a Plan to Regain Compliance
Wednesday November 30, 2016
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company" , today announced receipt of notification (the "Deficiency Letter" from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.
Specifically, the Deficiency Letter indicated that the Company is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide (requiring stockholders' equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years). As of September 30, 2016, the Company had stockholders' equity of approximately $5.3 million. The Company is required to submit a plan to the NYSE MKT by December 23, 2016 advising of actions it has taken or will take to regain compliance with the continued listing standards by May 23, 2018. The Company's management is exploring its options moving forward. Currently, the Company intends to submit a plan by the December 23, 2016 deadline. If the Company does not submit a plan or if the plan is not accepted, NYSE Regulation will take action to cite the Company's noncompliance with Section 1003(a)(iii) of the NYSE MKT Company Guide as an additional basis for delisting, in addition to the "abnormally low" trading price of the shares of the Company's common stock, which was the basis for NYSE MKT's determination on October 13, 2016 to immediately suspend trading of the Company's common stock and class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (the "Listed Warrants" and commence delisting procedures, which determination the Company is currently appealing. If the plan is accepted, the Company will be subject to periodic reviews and continued compliance with the plan. If the Company is not in compliance with the continued listing standards as of May 23, 2018, or does not make progress consistent with the plan, NYSE MKT will initiate delisting proceedings.
The Company's common stock and Listed Warrants currently trade on the OTCQB under the symbols "PVCT" and "PVCTWS," respectively, and the Company expects that these securities will continue to trade on the OTCQB while it attempts to regain compliance with the NYSE MKT listing standards noted above. The NYSE MKT notification does not affect the Company's business operations or its SEC reporting requirements.
The complete press release is available at http://www.provectusbio.com/news/press-releas...20161130-1 on the Provectus website.
Read More: http://investorshangout.com/post/view?id=4197...z4RX09DT00
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼